ストックスクリーナーアプリを入手
4.40
0.23%
-0.010
Camp 4 Therapeutics Corp (CAMP) 最新ニュース
A potential treatment for a genetic disorder is expected to enter human testing late in 2026. CAMP4 will discuss it Sept. 28. - Stock Titan
Camp4 CFO Kelly Gold buys $39,600 in company stock By Investing.com - Investing.com Canada
Camp4 CFO Kelly Gold buys $39,600 in company stock - Investing.com
CAMP4 to Participate in Upcoming Investor Conferences - GlobeNewswire
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock By Investing.com - Investing.com South Africa
Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock - Investing.com
5AM nears 10% cap in Camp4 Therapeutics (CAMP) while unloading shares - Stock Titan
Camp4 Therapeutics director Andrew Schwab sells $45 in shares By Investing.com - Investing.com Canada
Camp4 Therapeutics Corp presents new approach to treat haploinsufficient diseases via SYNGAP program - Traders Union
Balyasny Asset Management L.P. Reduces Stake in Camp4 Therapeuti - GuruFocus
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com - Investing.com Australia
Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock - Investing.com
Camp4 Therapeutics (NASDAQ: CAMP) backer sees stake diluted after new share sales - Stock Titan
Camp4 Therapeutics (NASDAQ: CAMP) insider to sell 1,738 shares - Stock Titan
ETFs Investing in CAMP4 Therapeutics Corporation Stocks - TradingView
Analysts’ Top NA Picks: CAMP4 Therapeutics Corporation (CAMP), Wayfair (W) - The Globe and Mail
CAMP4 Therapeutics (CAMP) Jumps 8% to $4.86: Key Levels to WatchMomentum Stock Picks - vinanet.vn
Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates - scanx.trade
CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges - Stock Titan
CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028 - Stock Titan
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
Camp4 Therapeutics Corp SEC Filing (Aug 13, 2026) - Stock Titan
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares - Stock Titan
CAMP4 Therapeutics Corp expected to post a loss of 21 cents a shareEarnings Preview - TradingView
CAMP Q1 2026 Earnings: EPS Miss Deepens 49.4% as Pre-Revenue Biotech Navigates Pipeline ProgressEarnings Surprise Stocks - vinanet.vn
Camp4 Therapeutics Corp CEO to launch new SYNGAP1 clinical trial in upcoming initiative - Traders Union
Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
CAMP4 Therapeutics (NASDAQ:CAMP) CEO Josh Mandel-Brehm Purchases 6,551 Shares - MarketBeat
Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock - MarketBeat
Insider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) CFO Buys $10,809.15 in Stock - MarketBeat
5AM Ventures group updates CAMP4 Therapeutics (CAMP) stake and warrant terms - Stock Titan
CAMP4 closes $50.1 million second tranche of private placement By Investing.com - Investing.com India
CAMP4 Therapeutics Secures $50 Million Private Financing - TipRanks
CAMP4 Therapeutics Closes Second Tranche of Private Placement, Raising $50.1 Million to Advance CMP-002 Development - Quiver Quantitative
Camp4 Therapeutics Raises $50.1 Million in Second Closing of Private Placement - TradingView
CAMP4 Therapeutics (Nasdaq: CAMP) raises $50.1M in second private placement closing - Stock Titan
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement - globenewswire.com
Camp4 Therapeutics Corp leverages regulatory RNA to target genetic root causes - Traders Union
CAMP4 Therapeutics (CAMP) Gains 3% as Stock Approaches Resistance at $3.54Time Weighted Price - vinanet.vn
CAMP4 Therapeutics Corporation Revenue Breakdown – NASDAQ:CAMP - TradingView
CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Forecasts - Yahoo! Finance Canada
Analysts Are Bullish on These NA Stocks: SpaceX (SPCX), CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
Camp4 Moves Into Human Trials -- The Upside Is Underpriced (NASDAQ:CAMP) - Seeking Alpha
CAMP4 receives Australian clearance for SYNGAP1 therapy trial By Investing.com - Investing.com UK
CAMP4 THERAPEUTICS CORPORATION (CAMP) stock price, news, quote and history - Yahoo Finance UK
Camp4 Therapeutics’ lead ASO approved for clinical trials in Australia - BioWorld News
CAMP4 receives Australian clearance for SYNGAP1 therapy trial - Investing.com Australia
Camp4 Therapeutics Corp secures clinical trial approval for first SYNGAP1 disease-modifying therapy in Australia - Traders Union
CAMP4 Therapeutics (CAMP) clears CMP-002 trial in Australia, eyes $50.1M raise - Stock Titan
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder - globenewswire.com
CAMP4 Therapeutics Corp (CAMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CAMP4 Therapeutics Corp (CAMP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CAMP|CAMP4 Therapeutics Corp|Price:3.440|Chg%:+0.280 - TradingKey
CAMP4 gains Australian clearance, enabling CMP-002 trial and financing - TipRanks
CAMP|CAMP4 Therapeutics Corp|Price:3.160|Chg%:+0.150 - TradingKey
CAMP4 Therapeutics Corp (CAMP) Cash Flow - TradingKey
5.27%
18.75%
大文字化:
|
ボリューム (24 時間):